IP Library Granted Patent US 9,182,418
Granted Patent B2
US 9,182,418 · App. 14/170,268 · Granted Nov 10, 2015

Non-precipitating bodily fluid analysis system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,182,418
App. No.
14/170,268
Granted
Nov 10, 2015
Kind
B2
Abstract

A bodily fluid analyzer including a dry test strip impregnated with a reagent providing a non-precipitating reaction to exclude non-desired analytes. The reagent complexes the non-desired analytes so they remain in solution but cannot participate in the test reaction. Red blood cells are removed from the detection area by slowing their vertical movement and stopping flow when the detection membrane is saturated.

Claims (26)

1. A method of determining a characteristic of low density lipoprotein (LDL) from a plurality of analytes in a bodily fluid, said method comprising:

providing said bodily fluid containing said LDL and one or more non-selected analytes;

providing a dry test strip having a well with porous layers within said well that allow said analytes to pass creating a vertical column of said analytes having a defined volume;

applying said bodily fluid to said well in said dry test strip; and

reacting said LDL in the bodily fluid with a reactant in said dry test strip to provide an indication of said characteristic while preventing said one or more non-selected analytes from participating in said reaction, without precipitating said one or more non-selected analytes, wherein said preventing comprises complexing said non-selected analyte so that it cannot participate in said reaction and wherein said complexing comprises interacting said non-selected analytes with a polyanion, said polyanion is an anionic polymer, and said anionic polymer has a molecular weight between 50,000 and 8,000 and the non-selected analytes include HDL analytes, VLDL (very low density lipoproteins), ILDL (intermediate density lipoproteins), and chylomicrons (big, tryglyceride-rich lipoproteins).

2. A method as in claim 1 wherein said bodily fluid is blood.

3. A method as in claim 2 wherein said one or more non-selected analytes are selected from the group consisting of HDL analytes, VLDL (very low density lipoproteins), ILDL (intermediate density lipoproteins), and chylomicrons (big, tryglyceride-rich lipoproteins).

4. A method as in claim 1 wherein said indication is an optical indication.

5. A method as in claim 4 wherein said optical indication is a colorimetric indication.

6. A method as in claim 1 wherein said anionic polymer has a molecular weight between 25,000 and 10,000.

7. A method as in claim 1 wherein said anionic polymer has a molecular weight between 18,000 and 12,000.

8. A method as in claim 1 wherein said anionic polymer comprises dextran sulphate.

9. A method as in claim 1 wherein said reacting further comprises reacting with a divalent metal.

10. A method as in claim 1 wherein said complexing comprises exposing said non-selected analyte to a reagent comprising dextran sulphate and a divalent metal.

11. A method as in claim 1 wherein said selected analyte is LDL and said complexing comprises exposing said bodily fluid to a reagent comprising dextran sulphate, a divalent metal; and wherein said method further comprises exposing said LDL to a destabilizing compound.

12. A method as in claim 11 wherein said destabilizing compound is selected from the group consisting of glycols, polypropylenes, and polyethylenes.

13. A method as in claim 1 wherein said preventing further comprises flowing said complexed non-selected analytes through an asymmetric membrane to slow their flow.

14. A method as in claim 1 wherein said reacting comprises destabilizing said LDL so that it reacts more quickly with said reactant.

15. A method as in claim 14 wherein said destabilizing is performed with a surfactant.

16. A method as in claim 14 wherein said destabilizing is performed with a compound selected from the group consisting of glycols, polypropylenes, and polyethylenes.

17. A method of determining a characteristic of low density lipoprotein (LDL) from a plurality of analytes in a bodily fluid, said method comprising:

providing said bodily fluid containing said LDL and one or more non-selected analytes;

providing a dry test strip having a well with porous layers within said well that allow said analytes to pass creating a vertical column of said analytes having a defined volume;

applying said bodily fluid to said well in said dry test strip; and

reacting said LDL in the bodily fluid with a reactant in said dry test strip to provide an indication of said characteristic while preventing said one or more non-selected analytes from participating in said reaction, without precipitating said one or more non-selected analytes, wherein said preventing comprises complexing said non-selected analyte so that it cannot participate in said reaction and wherein said selected analyte is LDL and said complexing comprises exposing said bodily fluid to an anionic polymer reagent comprising dextran sulphate, a divalent metal; and wherein said method further comprises exposing said LDL to a destabilizing compound, and the destabilizing compound is a polyoxyethylene-polyoxypropylene-polyoxyethylene hybrid.

18. The method of claim 17 , wherein said anionic polymer has a molecular weight between 50,000 and 8,000.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Jan 26, 2023
From: PNC BANK, NATIONAL ASSOCIATION ,AS AGENT
To: POLYMER TECHNOLOGY SYSTEMS,INC.
Reel/Frame 062496/0384 →
SECURITY INTEREST Recorded Jun 4, 2014
From: POLYMER TECHNOLOGY SYSTEMS, INC.
To: PNC BANK, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 033083/0614 →